You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

192 Results
Drug
Other Name(s): Cabometyx®
May 2025
Drug
Other Name(s): Tecentriq™
May 2025
Drug
Other Name(s): Imfinzi®
May 2025
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®
May 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
May 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    dexamethasone
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
May 2025

Pages